Literature DB >> 7235820

Disopyramide-induced Torsade de Pointes.

D Tzivoni, A Keren, S Stern, S Gottlieb.   

Abstract

Recurrent ventricular tachycardia (torsade de pointes) is a serious and sometimes fatal arrhythmia occurring usually with quinidine therapy. Four patients experienced ventricular tachycardia after receiving conventional doses of disopyramide phosphate (600 mg/day) for recurrent atrial fibrillation-two of them in combination with amiodarone hydrochloride. Isoproterenol hydrochloride infusion was effective in three patients, while ventricular pacing promptly abolished ventricular ectopic beats and the ventricular tachycardia in the fourth patient. Torsade de pointes is more likely to occur in patients with severe repolarization delay and sinus bradycardia or atrioventricular block, and its appearance in four patients within a period of nine months after the introduction of disopyramide treatment in our service raises the possibility that this is not a rare complication of this drug, especially if used in combination with other QT interval-prolonging agents.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7235820

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  9 in total

Review 1.  Pharmacological control of rate and maintenance of sinus rhythm.

Authors:  M D Ezekowitz; R Lampert
Journal:  J Thromb Thrombolysis       Date:  1999-01       Impact factor: 2.300

2.  Torsade de Pointes--2 case reports.

Authors:  F Mulcahy; E J Marshall; M Bakshi; B McMahon; M Walsh
Journal:  Ir J Med Sci       Date:  1982-12       Impact factor: 1.568

Review 3.  Drug interactions with cisapride: clinical implications.

Authors:  E L Michalets; C R Williams
Journal:  Clin Pharmacokinet       Date:  2000-07       Impact factor: 6.447

Review 4.  Disopyramide. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiac arrhythmias.

Authors:  R N Brogden; P A Todd
Journal:  Drugs       Date:  1987-08       Impact factor: 9.546

Review 5.  Cardiac repolarisation and drug regulation: assessing cardiac safety 10 years after the CPMP guidance.

Authors:  Rashmi R Shah
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

6.  Terminology of torsades de pointes.

Authors:  D Tzivoni; A Keren; S Banai; S Stern
Journal:  Cardiovasc Drugs Ther       Date:  1991-04       Impact factor: 3.727

Review 7.  Torsades de pointes: prevention and therapy.

Authors:  A Keren; D Tzivoni
Journal:  Cardiovasc Drugs Ther       Date:  1991-04       Impact factor: 3.727

Review 8.  Torsade de pointes. Mechanisms and management.

Authors:  C Napolitano; S G Priori; P J Schwartz
Journal:  Drugs       Date:  1994-01       Impact factor: 9.546

9.  Safety of Outpatient Initiation of Disopyramide for Obstructive Hypertrophic Cardiomyopathy Patients.

Authors:  Arnon Adler; Dana Fourey; Adaya Weissler-Snir; Waseem Hindieh; Raymond H Chan; Michael H Gollob; Harry Rakowski
Journal:  J Am Heart Assoc       Date:  2017-05-26       Impact factor: 5.501

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.